Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Symbol: 002399.SZ
SHZ
9.37
CNYMarktpreis heute
-17.2720
P/E-Verhältnis
-0.4195
PEG-Verhältnis
12.33B
MRK Kapital
- 0.01%
DIV Rendite
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10139.37 | 2265.8 | 3450.4 | 3925.4 | ||||||||||||||||||
balance-sheet.row.short-term-investments | 1631.92 | 414.2 | 1311.6 | 981.2 | ||||||||||||||||||
balance-sheet.row.net-receivables | 6253.86 | 1528.6 | 1946.6 | 1985.5 | ||||||||||||||||||
balance-sheet.row.inventory | 30150.6 | 6654.1 | 6843.9 | 4707.5 | ||||||||||||||||||
balance-sheet.row.other-current-assets | 857.6 | 155.4 | 148.7 | 151.2 | ||||||||||||||||||
balance-sheet.row.total-current-assets | 47401.43 | 10603.9 | 12389.6 | 10769.7 | ||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 10261.67 | 2634.2 | 2477.3 | 2537.2 | ||||||||||||||||||
balance-sheet.row.goodwill | 9504.81 | 2322.4 | 2351 | 2152.2 | ||||||||||||||||||
balance-sheet.row.intangible-assets | 2153.33 | 493.2 | 571.7 | 586.7 | ||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 11658.14 | 2815.6 | 2922.6 | 2738.9 | ||||||||||||||||||
balance-sheet.row.long-term-investments | 8198.95 | 2514.9 | 1152.5 | 1636.7 | ||||||||||||||||||
balance-sheet.row.tax-assets | 753.39 | 320.5 | 139.6 | 121.7 | ||||||||||||||||||
balance-sheet.row.other-non-current-assets | 2460.85 | 314.3 | 1732.5 | 1304.1 | ||||||||||||||||||
balance-sheet.row.total-non-current-assets | 33333 | 8599.5 | 8424.6 | 8338.5 | ||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.total-assets | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.account-payables | 1374.71 | 302.2 | 427.4 | 385.8 | ||||||||||||||||||
balance-sheet.row.short-term-debt | 14923.61 | 3662.4 | 4056.5 | 3299.9 | ||||||||||||||||||
balance-sheet.row.tax-payables | 525.27 | 157.2 | 141.8 | 158.7 | ||||||||||||||||||
balance-sheet.row.long-term-debt-total | 8990.3 | 1810 | 2407.4 | 2354.3 | ||||||||||||||||||
Deferred Revenue Non Current | 127.65 | 30.4 | 32.5 | 16.7 | ||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1232.54 | - | - | - | ||||||||||||||||||
balance-sheet.row.other-current-liab | 3123.05 | 655.4 | 658 | 3.8 | ||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 10620.06 | 2198 | 2830.8 | 2793.4 | ||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 383.85 | 90.4 | 110.7 | 104 | ||||||||||||||||||
balance-sheet.row.total-liab | 31250.86 | 7184.2 | 8406.6 | 7584.9 | ||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||||
balance-sheet.row.common-stock | 5869.18 | 1467.3 | 1467.3 | 1467.3 | ||||||||||||||||||
balance-sheet.row.retained-earnings | 14530.6 | 1543.2 | 4314.1 | 3647 | ||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 9077.94 | 1373.8 | 843.4 | 563.9 | ||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 19614.97 | 7528.9 | 5686.1 | 5733.2 | ||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 49092.69 | 11913.1 | 12310.9 | 11411.4 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 80734.43 | 19203.4 | 20814.2 | 19108.2 | ||||||||||||||||||
balance-sheet.row.minority-interest | 360.05 | 75.2 | 96.7 | 112 | ||||||||||||||||||
balance-sheet.row.total-equity | 49452.73 | 11988.4 | 12407.6 | 11523.3 | ||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 80734.43 | - | - | - | ||||||||||||||||||
Total Investments | 9830.87 | 2929.1 | 2464.1 | 2617.8 | ||||||||||||||||||
balance-sheet.row.total-debt | 24004.33 | 5562.8 | 6463.9 | 5654.2 | ||||||||||||||||||
balance-sheet.row.net-debt | 15496.87 | 3711.2 | 4325.1 | 2709.9 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -783.26 | -783.3 | 714.7 | 233.4 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 371.05 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 3.98 | -237.6 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | -1332.4 | 43.3 | 0.2 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | -349.12 | -563.1 | -2311.3 | -1125.1 | ||||||||||||||||||
cash-flows.row.account-receivables | 270.55 | 270.5 | -176.1 | 141.8 | ||||||||||||||||||
cash-flows.row.inventory | -619.67 | -619.7 | -2151.6 | -1520.2 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | -213.9 | 59.7 | 423.9 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -43.3 | -170.6 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 548.74 | 3003.1 | 532.3 | 752.7 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 678.73 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 2.34 | -4.9 | 0 | 1.7 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | -677.26 | -758.2 | -4482.7 | -2370.2 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 1647.35 | 2349.3 | 4210.7 | 3305.1 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 694.02 | -0.1 | 744.2 | -22.9 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 1221.57 | 1141.2 | 249.8 | 719.9 | ||||||||||||||||||
cash-flows.row.debt-repayment | -5991.71 | -730.9 | -6036.3 | -3730.6 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | -425.89 | -146.7 | -251 | -412.5 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 5207.43 | -325.4 | 6616.8 | 3642 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -1210.17 | -1203 | 329.6 | -501.1 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 36.32 | 36.3 | 17.3 | -62.8 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 445.94 | -287.1 | -159.9 | 149.4 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 6714.63 | 1851.6 | 1319.7 | 1479.6 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 6268.69 | 2138.8 | 1479.6 | 1330.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 678.73 | 471.4 | -756.6 | -6.6 | ||||||||||||||||||
cash-flows.row.capital-expenditure | -444.88 | -444.9 | -222.4 | -193.9 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 233.86 | 26.5 | -979 | -200.5 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 5434.47 | 5421.7 | 7159.4 | 6365.2 | ||||||||||||||||||
income-statement-row.row.cost-of-revenue | 3670.52 | 3746.3 | 4825 | 4332.1 | ||||||||||||||||||
income-statement-row.row.gross-profit | 1763.95 | 1675.4 | 2334.4 | 2033 | ||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||||
income-statement-row.row.research-development | 179.91 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-general-administrative | 458.57 | - | - | - | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.operating-expenses | 2128.44 | 1935.4 | 1211.9 | 1068.9 | ||||||||||||||||||
income-statement-row.row.cost-and-expenses | 5798.96 | 5681.6 | 6036.9 | 5401 | ||||||||||||||||||
income-statement-row.row.interest-income | -39.52 | -39.5 | 54.1 | 54.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 517.42 | - | - | - | ||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||||
income-statement-row.row.other-operating-expenses | -985.68 | -855.4 | 294.7 | 274.9 | ||||||||||||||||||
income-statement-row.row.total-operating-expenses | -89.2 | -220.4 | -305.3 | -550.9 | ||||||||||||||||||
income-statement-row.row.interest-expense | 223.22 | 223.2 | 235.2 | 201.6 | ||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 241.34 | 384.7 | 307.7 | 302.7 | ||||||||||||||||||
income-statement-row.row.ebitda-caps | -433.09 | - | - | - | ||||||||||||||||||
income-statement-row.row.operating-income | -674.43 | -259.9 | 1135.1 | 773.2 | ||||||||||||||||||
income-statement-row.row.income-before-tax | -763.62 | -480.4 | 829.9 | 222.3 | ||||||||||||||||||
income-statement-row.row.income-tax-expense | -126.17 | -126.2 | 115.2 | -11.1 | ||||||||||||||||||
income-statement-row.row.net-income | -783.26 | -783.3 | 727.4 | 240.8 |
Häufig gestellte Frage
Wie hoch ist die Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) Gesamtvermögen?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) Gesamtvermögen ist 19203415131.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist 2721572551.000.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.325.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 0.159.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist -0.144.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist -0.124.
Was ist der Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (002399.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist -783258039.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 5562816036.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 1935358054.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 1851642224.000.